Grant Award Details

Extending Immune-Evasive Human Islet-Like Organoids (HILOs) Survival and Function as a Cure for T1D
Grant Number: 
DISC2-13213
Project Objective: 
  • The overall objective of this project is to maximize the therapeutic viability of an immune-shielded, glucose-responsive human islet-like organoids (HILOs) as a cure for type 1 diabetes by demonstrating their efficacy and long-term survival.
Investigator: 
Disease Focus: 
Diabetes
Metabolic Disorders
Type 1 diabetes
Human Stem Cell Use: 
Embryonic Stem Cell
Award Value: 
$1,523,285
Status: 
Active

Grant Application Details

Application Title: 
  • Extending Immune-Evasive Human Islet-Like Organoids (HILOs) Survival and Function as a Cure for T1D
Public Abstract: 

Research Objective

Determine optimal islet transplant conditions and systemic treatments that promote graft survival upon transplantation into immune-competent diabetic subjects.

Impact

Our proposal will optimize the generation and viability of an unlimited, reproducible source of human engineered islets for transplantation.

Major Proposed Activities

  • Demonstrate improved HILO graft survival with FGF1 coating
  • Prolong grafted HILO survival by reducing metabolic insulin demand
Statement of Benefit to California: 

Diabetes affects 3 million people in California. Type 1 diabetes is a particular burden as it requires life-long administration of insulin. Allo-transplantation of islets is limited by availability of donor cells. This proposal will facilitate the generation of functional ESC-derived islet-like organoids as an unlimited, reproducible source and optimize methods to increase functionality and viability upon transplantation into diabetic patients.